Back

Angiotensin receptor-neprilysin inhibitor (Sacubitril/Valsartan) in cancer therapy-related cardiac dysfunction: real-world experience from a nurse-led cardio-oncology clinic

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity and development of heart failure Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Priya Reehal

Royal Brompton Hospital Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Heart rate variability-based prediction of early cardiotoxicity in breast-cancer patients treated with anthracyclines and trastuzumab
Doctor N. Espinola-Zavaleta (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Low clinical utility of global longitudinal strain in a real-world breast cancer population
Doctor L. Ruane (Brisbane, AU)
Abstract Slides Video
Presentation thumbnail
Does HFpEF represent a risk factor and a marker of cardiotoxicity in patients undergoing cancer treatment?
Doctor B. von Kemp (Brussels, BE)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics, resource use, and diagnostic accuracy of natriuretic peptides in cancer patients presenting with acute dyspnea to the Emergency Department
Doctor P. Lopez Ayala (Basel, CH)
Abstract Slides Video
Presentation thumbnail
miRNAs profile as a signature for cardiovascular disease in long-term breast cancer female survivors: a pilot study
Doctor A. Greatti (Ferrara, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity and development of heart failure

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Cardioprotective strategies and outcomes in cancer therapy-related cardiac dysfunction: insights from a single-center study
thumbnail
Congress Presentation
Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort
thumbnail
Congress Presentation
Use of guideline directed medical therapy and clinical outcomes in cancer patients with de novo heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources